Literature DB >> 10348767

Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance.

N I Girgis1, T Butler, R W Frenck, Y Sultan, F M Brown, D Tribble, R Khakhria.   

Abstract

To compare clinical and bacteriological efficacies of azithromycin and ciprofloxacin for typhoid fever, 123 adults with fever and signs of uncomplicated typhoid fever were entered into a randomized trial. Cultures of blood were positive for Salmonella typhi in 59 patients and for S. paratyphi A in 3 cases; stool cultures were positive for S. typhi in 11 cases and for S. paratyphi A in 1 case. Multiple-drug resistance (MDR; resistance to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole) was present in isolates of 21 of 64 patients with positive cultures. Of these 64 patients, 36 received 1 g of azithromycin orally once on the first day, followed by 500 mg given orally once daily on the next 6 days; 28 patients received 500 mg of ciprofloxacin orally twice daily for 7 days. Blood cultures were repeated on days 4 and 10 after the start of therapy, and stool cultures were done on days 4, 10, and 28 after the start of therapy. All patients in both groups improved during therapy and were cured. Defervescence (maximum daily temperatures of </=38 degrees C) occurred at the following times [mean +/- standard deviation (range)] after the start of therapy: 3.8 +/- 1.1 (2 to 7) days with azithromycin and 3.3 +/- 1.0 (1 to 5) days with ciprofloxacin. No relapses were detected. Cultures of blood and stool during and after therapy were negative in all cases, except for one patient treated with azithromycin who had a positive blood culture on day 4. These results indicated that azithromycin and ciprofloxacin were similarly effective, both clinically and bacteriologically, against typhoid fever caused by both sensitive organisms and MDR S. typhi.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348767      PMCID: PMC89293          DOI: 10.1128/AAC.43.6.1441

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996.

Authors:  E J Threlfall; A Graham; T Cheasty; L R Ward; B Rowe
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

2.  Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone.

Authors:  Z A Bhutta; I A Khan; A M Molla
Journal:  Pediatr Infect Dis J       Date:  1994-11       Impact factor: 2.129

3.  Sample size nomograms for interpreting negative clinical studies.

Authors:  M J Young; E A Bresnitz; B L Strom
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

4.  Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea.

Authors:  T Butler; A Islam; I Kabir; P K Jones
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

5.  In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against Salmonella typhi.

Authors:  B Metchock
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever.

Authors:  M R Wallace; A A Yousif; G A Mahroos; T Mapes; E J Threlfall; B Rowe; K C Hyams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

7.  Cefixime in the treatment of enteric fever in children.

Authors:  N I Girgis; M E Kilpatrick; Z Farid; Y Sultan; J K Podgore
Journal:  Drugs Exp Clin Res       Date:  1993

8.  Comparative efficacies of azithromycin and ciprofloxacin against experimental Salmonella typhimurium infection in mice.

Authors:  T Butler; A E Girard
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

9.  Randomized clinical trial of furazolidone for typhoid fever in children.

Authors:  P Dutta; R Rasaily; M R Saha; U Mitra; B Manna; S Chakraborty; A Mukherjee
Journal:  Scand J Gastroenterol       Date:  1993-02       Impact factor: 2.423

10.  Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever.

Authors:  M D Smith; N M Duong; N T Hoa; J Wain; H D Ha; T S Diep; N P Day; T T Hien; N J White
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

View more
  26 in total

1.  Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused by Salmonella enterica serotype Paratyphi A.

Authors:  Shelanah Fernando; Janice Gail Molland; Thomas Gottlieb
Journal:  Pathog Glob Health       Date:  2012-10       Impact factor: 2.894

2.  A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.

Authors:  N T Chinh; C M Parry; N T Ly; H D Ha; M X Thong; T S Diep; J Wain; N J White; J J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.

Authors:  Christopher M Parry; Vo Anh Ho; Le Thi Phuong; Phan Van Be Bay; Mai Ngoc Lanh; Le Thanh Tung; Nguyen Thi Hong Tham; John Wain; Tran Tinh Hien; Jeremy J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

4.  Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States.

Authors:  Maria Sjölund-Karlsson; Kevin Joyce; Karen Blickenstaff; Takiyah Ball; Jovita Haro; Felicita M Medalla; Paula Fedorka-Cray; Shaohua Zhao; John A Crump; Jean M Whichard
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

Review 5.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 6.  WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever).

Authors:  Emmanuel E Effa; Hasifa Bukirwa
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

Review 7.  Current trends in typhoid Fever.

Authors:  Nancy F Crum
Journal:  Curr Gastroenterol Rep       Date:  2003-08

8.  An imported enteric fever caused by a quinolone-resistant Salmonella Typhi.

Authors:  Ali Mohammed Somily
Journal:  Ann Saudi Med       Date:  2010 Jul-Aug       Impact factor: 1.526

9.  Quinolone and cephalosporin resistance in enteric Fever.

Authors:  Malini Rajinder Capoor; Deepthi Nair
Journal:  J Glob Infect Dis       Date:  2010-09

10.  A comparative study of efficacy and safety of azithromycin and ofloxacin in uncomplicated typhoid Fever: a randomised, open labelled study.

Authors:  Manish Chandey; A S Multani
Journal:  J Clin Diagn Res       Date:  2012-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.